详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Multimodal profiling identifies CD4+CXCR5+PD-1- Tfh cells as prognostic and predictive biomarkers in diffuse large B-cell lymphoma

文献详情

资源类型：

Pubmed体系：

收录情况： ◇ 统计源期刊 ◇ CSCD-C ◇ 卓越：领军期刊 ◇ 中华系列

作者：

机构： [1]State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China [2]Department of Medical Oncology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, Sichuan 610041, China [3]Department of Clinical Laboratory, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, Sichuan 610041, China [4]Institute of Science and Technology for Brain-Inspired Intelligence, Fudan University, Shanghai 200433, China [5]West China School of Public Health, West China Fourth Hospital, and State Key Laboratory of Biotherapy, Sichuan University, Chengdu, Sichuan 610041, China [6]Zhejiang University-University of Edinburgh Institute, Zhejiang University School of Medicine, Zhejiang University, Haining, Zhejiang 314400, China [7]Division of Medical Oncology, Cancer Center, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China [8]Department of Cardiology of The Second Affiliated Hospital, School of Medicine, Zhejiang University/State Key Laboratory of Transvascular Implantation Devices/ Cardiac Function Regeneration Key Laboratory of Zhejiang Province, Hangzhou, Zhejiang 310009, China [9]Department of Pancreatic Surgery, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China.

出处：

DOI：

ISSN：

摘要：

To the Editor: Diffuse large B-cell lymphoma (DLBCL) is characterized by high heterogeneity. Elucidation of the underlying cause of the biological mechanism of DLBCL, is clinical. Here, we utilized single-cell RNA sequencing (scRNA-seq), DNA sequencing, and multiplex immunohistochemistry (mIHC) to investigate the cellular composition of primary and relapsed/refractory DLBCL (R/R DLBCL)). We conducted a series of validations on published single-cell data and bulk sequencing data, performed in vivo validations in mouse models, and used a deep generative network model for prediction and identification. Detailed information is presented in Supplementary Methods, Supplementary Figure 1, and Supplementary Table 1, http://links.lww.com/CM9/C618. The study protocol was approved by the Ethics Committee of Sichuan Cancer Hospital (SCCHEC-02-2022-009) and the West China Hospital Animal Ethics Committee (2020361A). Given the retrospective nature, the informed consent was waived.

基金：

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2025]版：

大类 | 2 区医学

小类 | 2 区医学：内科

最新[2025]版：

大类 | 2 区医学

小类 | 2 区医学：内科

第一作者：

第一作者机构： [1]State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China [2]Department of Medical Oncology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, Sichuan 610041, China

共同第一作者：

通讯作者：

通讯机构： [1]State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China [9]Department of Pancreatic Surgery, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China.

推荐引用方式(GB/T 7714)：

APA：

MLA：